One Day MD (onedaymd.substack.com), 2025-10-26: Compilation of more than 100 patient stories of grade 4 brain cancer treated with ivermectin and mebendazole, presented one case at a time with age, country, drugs and reported outcome; no verification of any case.
Drawing from a surge of compelling success stories documented from 2019 (METRICS study) to 2025, this article explores more than 100 real-world case reports of patients achieving remarkable outcomes
One Day MD (onedaymd.substack.com), 2025-10-26: Compilation of more than 100 patient stories of grade 4 brain cancer treated with ivermectin and mebendazole, presented one case at a time with age, country, drugs and reported outcome; no verification of any case. C4. Study type: testimonial compilation (not a study); n stated as 103 in the page title and 110 in the article heading; country of each patient varies and is given per case (Canada, Turkey, USA, Brazil and others). Doses: individual testimonial doses; the page itself does not tabulate a single dose. Other treatments: per case, described as 'often alongside or in lieu of conventional treatments'. Outcome: as reported by each patient (stabilisation, shrinkage, remission), measured by patient report and, in some cases, scans. PATIENT-REPORTED, NOT INDEPENDENTLY VERIFIED. Funding/disclosures: none stated; the page is a commercial-adjacent publication that sells supplement/consulting material elsewhere on the site. The heading text and the Contents list disagree on the count (103 vs 110) – recorded as published. Also filed as IVD-49 (claims C4, C7).
